The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
The Myeloproliferative Disorders
Abstract
The discovery of an identical mutation (V617F) of the JAK2 gene in patients with polycythemia vera, essential thrombocythemia, and myelofibrosis — the principal Philadelphia chromosome–negative myeloproliferative disorders — has greatly advanced our understanding of these conditions. This article reviews the legacy of this discovery and how it has changed our view of the origins, interrelations, and management of the myeloproliferative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., & Ihle, J. N. (1993) · Cell · doi:10.1016/0092-8674(93)90414-l · Cited by 1,194
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Signaling through the JAK/STAT pathway, recent advances and future challenges
Kisseleva, T., Bhattacharya, S., Braunstein, J., & Schindler, C. W. (2002) · Gene · doi:10.1016/s0378-1119(02)00398-0 · Cited by 1,154
Editorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Self-citationJak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747
Myelofibrosis with Myeloid Metaplasia
Tefferi, A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421706 · Cited by 740
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., & Barbui, T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.062 · Cited by 726
Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice
Socolovsky, M., Fallon, A. E. J., Wang, S., Brugnara, C., & Lodish, H. F. (1999) · Cell · doi:10.1016/s0092-8674(00)81013-2 · Cited by 696
Ineffective erythropoiesis in Stat5a−/−5b−/− mice due to decreased survival of early erythroblasts
Socolovsky, M., Nam, H.-S., Fleming, M. D., Haase, V. H., Brugnara, C., & Lodish, H. F. (2001) · Blood · doi:10.1182/blood.v98.12.3261 · Cited by 681
Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Self-citationPolycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease
Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197610212951702 · Cited by 640
Erythropoietin Receptor Activation by a Ligand-Induced Conformation Change
Remy, I., Wilson, I. A., & Michnick, S. W. (1999) · Science · doi:10.1126/science.283.5404.990 · Cited by 634
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Longley, B. J., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 552
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk, P. D., Goldberg, J. D., Donovan, P. B., Fruchtman, S. M., Berlin, N. I., & Wasserman, L. R. (1986) · PubMed · Cited by 493
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Lacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
Fialkow, P., Faguet, G., Jacobson, R., Vaidya, K., & Murphy, S. (1981) · Blood · doi:10.1182/blood.v58.5.916.916 · Cited by 386
Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H. M., & Issa, J.-P. J. (2005) · Blood · doi:10.1182/blood-2005-05-1800 · Cited by 369
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis
McMullin, M. F., Bareford, D., Campbell, P., Green, A. R., Harrison, C., Hunt, B., Oscier, D., Polkey, M. I., Reilly, J. T., Rosenthal, E., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05535.x · Cited by 343
Self-citationFGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Pardanani, A., Brockman, S. R., Paternoster, S. F., Flynn, H. C., Ketterling, R. P., Lasho, T. L., Ho, C.-L., Li, C.-Y., Dewald, G. W., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-03-0787 · Cited by 309
Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera
Moliterno, A. R., Hankins, W. D., & Spivak, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380903 · Cited by 302
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
Kralovics, R., Guan, Y., & Prchal, J. T. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00789-5 · Cited by 300
Scott, L. M., Scott, M. A., Campbell, P. J., & Green, A. R. (2006) · Blood · doi:10.1182/blood-2006-04-018259 · Cited by 294
Self-citationHuang, L. J.-S., Constantinescu, S. N., & Lodish, H. F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00401-4 · Cited by 294
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome
Patel, R. K., Lea, N. C., Heneghan, M. A., Westwood, N. B., Milojkovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gäken, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.008 · Cited by 277
Arellano‐Rodrigo, E., Álvarez‐Larrán, A., Reverter, J. C., Villamor, N., Colomer, D., & Cervantes, F. (2006) · PubMed · Cited by 269
Villeval, J.-L., Cohen-Solal, K., Tulliez, M., Giraudier, S., Guichard, J., Burstein, S. A., Cramer, E. M., Vainchenker, W., & Wendling, F. (1997) · Blood · doi:10.1182/blood.v90.11.4369 · Cited by 265
Levine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D. G., & Busque, L. (2006) · Blood · doi:10.1182/blood-2005-09-3900 · Cited by 241
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V, Longo, G., Bosi, A., & Vannucchi, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403902 · Cited by 229
Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera
Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I., & Fernández-Luna, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380902 · Cited by 229
Bellanne-Chantelot, C. (2006) · Blood · doi:10.1182/blood-2005-12-4852 · Cited by 227
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., & Barbui, T. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.01.015 · Cited by 225
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
Self-citationBüttner, C., Henz, B. M., Welker, P., Sepp, N. T., & Grabbe, J. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00414.x · Cited by 209
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05776.x · Cited by 207
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia
Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N. L., Petti, M. C., Pogliani, E., Ricetti, M., Rupoli, S., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01262.x · Cited by 202
Seubert, N., Royer, Y., Staerk, J., Kubatzky, K. F., Moucadel, V., Krishnakumar, S., Smith, S. O., & Constantinescu, S. N. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00389-7 · Cited by 187
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation
Kieslinger, M., Woldman, I., Moriggl, R., Hofmann, J., Marine, J.-C., Ihle, J. N., Beug, H., & Decker, T. (2000) · Genes & Development · doi:10.1101/gad.14.2.232 · Cited by 185
Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability
Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P. J., & Constantinescu, S. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501376200 · Cited by 176
Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. Knochenmarksbefund
Heuck, G. (1879) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01878089 · Cited by 171
Ugo, V., Marzac, C., Teyssandier, I., Larbret, F., Lécluse, Y., Debili, N., Vainchenker, W., & Casadevall, N. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.11.003 · Cited by 166
Bench, A. J., Nacheva, E. P., Hood, T. L., Holden, J. L., French, L., Swanton, S., Champion, K. M., Li, J., Whittaker, P., Stavrides, G., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203728 · Cited by 165
Self-citationJAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation
Staerk, J., Kallin, A., Demoulin, J.-B., Vainchenker, W., & Constantinescu, S. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500358200 · Cited by 163
Cervantes, F., Alvarez‐Larrán, A., Talarn, C., Gómez, M., & Montserrat, E. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03688.x · Cited by 159
Scott, L. M., Campbell, P. J., Baxter, E. J., Todd, T., Stephens, P., Edkins, S., Wooster, R., Stratton, M. R., Futreal, P. A., & Green, A. R. (2005) · Blood · doi:10.1182/blood-2005-05-2087 · Cited by 158
Self-citationStaerk, J., Lacout, C., Sato, T., Smith, S. O., Vainchenker, W., & Constantinescu, S. N. (2006) · Blood · doi:10.1182/blood-2005-06-2600 · Cited by 158
Cheung, B., Radia, D., Pantelidis, P., Yadegarfar, G., & Harrison, C. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05858.x · Cited by 156
James, C., Ugo, V., Casadevall, N., Constantinescu, S. N., & Vainchenker, W. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.10.003 · Cited by 150
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J. L., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404069 · Cited by 144
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Jones, A., Silver, R., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., et al. (2005) · Blood · doi:10.1182/blood-2005-09-3917 · Cited by 132
Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2
Goerttler, P. S., Kreutz, C., Donauer, J., Faller, D., Maiwald, T., März, E., Rumberger, B., Sparna, T., Schmitt-Graeff, A. H., Wilpert, J., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05416.x · Cited by 132
Labbaye, C., Valtieri, M., Barberi, T., Meccia, E., Masella, B., Pelosi, E., Condorelli, G., Testa, U., & Peschle, C. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117927 · Cited by 124
Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition
Walz, C., Crowley, B. J., Hudon, H. E., Gramlich, J. L., Neuberg, D. S., Podar, K., Griffin, J. D., & Sattler, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600064200 · Cited by 117
Vannucchi, A. M., Bianchi, L., Paoletti, F., Pancrazzi, A., Torre, E., Nishikawa, M., Zingariello, M., Baldassarre, A. D., Rana, R. A., Lorenzini, R., et al. (2005) · Blood · doi:10.1182/blood-2004-04-1320 · Cited by 115
STAT3 is constitutively active in some patients with Polycythemia rubra vera
Röder, S., Steimle, C., Meinhardt, G., & Pahl, H. L. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00637-3 · Cited by 107
Posttranslational Processing of the Thrombopoietin Receptor Is Impaired in Polycythemia Vera
Moliterno, A. R., & Spivak, J. L. (1999) · Blood · doi:10.1182/blood.v94.8.2555.420k14_2555_2561 · Cited by 104
Thiele, J., Kvasnicka, H. M., Zankovich, R., & Diehl, V. (2000) · PubMed · Cited by 99
Myklebust, J. H., Blomhoff, H. K., Rusten, L. S., Stokke, T., & Smeland, E. B. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00868-8 · Cited by 93
7 Molecular genetics and cytogenetics of myeloproliferative disorders
Bench, A. J., Nacheva, E. P., Champion, K. M., & Green, A. R. (1998) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(98)80041-3 · Cited by 91
Self-citationAn X chromosome gene regulates hematopoietic stem cell kinetics
Abkowitz, J. L., Taboada, M. R., Shelton, G. H., Catlin, S. N., Guttorp, P. M., & Kiklevich, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3862 · Cited by 90
Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management
Tefferi, A., & Murphy, S. (2001) · Blood Reviews · doi:10.1054/blre.2001.0158 · Cited by 87
Komura, E., Tonetti, C., Penard‐Lacronique, V., Chagraoui, H., Lacout, C., Couedic, J. P. L., Rameau, P., Debili, N., Vainchenker, W., & Giraudier, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2339 · Cited by 82
Lasho, T. L., Mesa, R. A., Gilliland, D. G., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05682.x · Cited by 60
Jak2 Tyrosine Kinase: A True Jak of All Trades?
Sandberg, E. M., Wallace, T. A., Godeny, M. D., VonDerLinden, D., & Sayeski, P. P. (2004) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:41:2:207 · Cited by 60
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7
Fröhling, S., Lipka, D. B., Käyser, S., Scholl, C., Schlenk, R. F., Döhner, H., Gilliland, D. G., Levine, R. L., & Döhner, K. (2006) · Blood · doi:10.1182/blood-2005-09-3644 · Cited by 58
Zeuner, A., Pedini, F., Signore, M., Ruscio, G., Messina, C. G. M., Tafuri, A., Girelli, G., Peschle, C., & Maria, R. D. (2005) · Blood · doi:10.1182/blood-2005-07-3037 · Cited by 54
Komura, E., Chagraoui, H., Mas, V. M., Blanchet, B., Sepulveda, P. D., Larbret, F., Larghero, J., Tulliez, M., Debili, N., Vainchenker, W., et al. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00085-7 · Cited by 53
Barbui, T. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.02.006 · Cited by 50
Evaluation of clonality in myeloid stem-cell disorders.
Gale, R. E. (1999) · PubMed · Cited by 36
The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.
Percy, M. J., Jones, F. G. C., Green, A. R., et al. (2006) · PubMed · Cited by 30
Self-citationSayer, M. S., Tilbrook, P. A., Spadaccini, A., Ingley, E., Sarna, M. K., Williams, J. H., Andrews, N. C., & Klinken, S. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908695199 · Cited by 16
Cited by
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Self-citation
Metadata
- Authors
- Campbell, P. J., & Green, A. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2452-2466
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2027613124
- Cited by
- 915
- References
- 98
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.